Starpharma completes A$32 million placement; SPP to follow
Starpharma is pleased to announce it has successfully raised A$32 million via a placement to international and domestic institutional, sophisticated and professional investors. It is intended to offer eligible existing shareholders the opportunity to also participate via a Share Purchase Plan to raise up to a further A$3 million.
AGM Chairman's address & CEO presentation; Results of AGM
Starpharma released its AGM Chairman's address and CEO presentation for the meeting held 10th November 2011. Results of voting were released following the meeting.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Quarterly Cash Flow Report for the period ended 30 September 2011.
ABC Radio Australia – Innovations: VivaGel Phase 3 Trial Gets Go-Ahead from FDA
ABC Radio Innovations Host Desley Blanch interviews Starpharma CEO Dr Jackie Fairley about the significance of Starpharma receiving FDA approval for the commencement of a Phase III clinical trial testing VivaGel for the treatment of Bacterial Vaginosis.
Go to the article (external link)
Starpharma secures FDA agreement on BV treatment Phase 3
Starpharma today announced that the Phase 3 clinical trial program for the VivaGel® bacterial vaginosis (BV) treatment program has been agreed with the US FDA following recent positive trial results and subsequent End of Phase 2 Meeting.
Ms Zita Peach appointed Non-Executive Director
Starpharma today announced the appointment of Ms Zita Peach as a Non-Executive Director.
Zita has more than 20 years of commercial experience in the pharmaceutical industry, particularly in marketing and business development, working for major industry players such as CSL Limited and Merck Sharp & Dohme (MSD), the Australian subsidiary of Merck Inc.
Starpharma elevated to S&P/ASX300 index
Starpharma has received notification that it will be elevated to the S&P/ASX 300 Index, effective from 19th September.
Starpharma Presents at Macquarie Investor Event
Starpharma is one of two healthcare companies presenting at the Macquarie Bank Australia and New Zealand Annual Corporate Day in Hong Kong and Singapore.
Commencing today, the presentation to institutional investors from the Asia region will include 33 companies from Australia, from either the top 50 or 200 ASX listed companies.
Annual Report and Full Year Financial Results
Starpharma today released its annual report and financial results for the year ended 30 June 2011.
Financial Results
- Cash position at end of year $18.9M
- Net cash burn for the year $3.9M
- Cash outflows from operations $6.5M
- Reported loss $8.9M
GSK Awarded Funds to Advance Dermal Treatment with Starpharma's Dendrimers
GlaxoSmithKline (GSK), and Starpharma today announced that GSK was awarded a grant to advance a dermal treatment based on Starpharma’s dendrimer drug delivery technology.
The funds will be used to support Starpharma’s synthesis of dendrimer-based drug candidates which will then be tested by Stiefel, a GSK company with a view to further development towards a dermal product.